Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Infuse Partners Ryan Reeves | “TransMedics has single-handedly changed the organ transplant process. In sticking with its mission to save lives, the company now owns 22 private jets and is doing roughly 30 organ transplants every single day. As density continues to grow, it becomes more difficult to compete with since the company's cost per transplant decreases relative to competitors. The market size is the biggest risk here but if TransMedics continues to enable donor after circulatory death transplants, it will grow the entire market as fewer organs will be wasted. BSD Analysis: TransMedics is redefining organ transplantation logistics with its Organ Care System. The moat is clinical outcomes plus surgeon trust—both hard to displace once proven. Growth is driven by procedure expansion, not price hikes. Execution risk sits in scaling operations and logistics flawlessly. Competition exists, but switching costs are high once systems are standardized. The failure mode is operational missteps that undermine confidence. The bull case is structurally higher transplant utilization. TransMedics is a platform built on trust, not hype.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
